Xiao Meng

Dr. Xiao Meng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Pharmacological Research
Verified
Journal Article
Open access
LMLianyue Ma
Lianyue Ma
WYWei Yang
Wei Yang
WGWei Gao
Wei Gao
XLXiangjuan Liu
Xiangjuan Liu
MDMei Dong
Mei Dong
XMXiao Meng
Xiao Meng
Interleukin-17 (IL-17), a pleiotropic cytokine produced by Th17 cells and innate immune cells, plays a pivotal role in cardiovascular diseases (CVDs) by bridging innate and adaptive immunity. Preclinical studies highlight its pro-inflammatory effects in atherosclerosis, myocardial infarction, hypertension, myocarditis, and heart failure, driving endothelial dysfunction, immune cell infiltration, oxidative stress, and tissue remodeling. Elevated IL-17 levels correlate with vulnerable plaque burden, adverse cardiac events, hypertension severity, and arrhythmogenesis. Paradoxically, IL-17 may stabilize plaques in specific contexts, underscoring its dual roles. Clinical data link IL-17 isoforms (e.g., IL-17A, IL-17E) to coronary artery disease progression and psychological comorbidities. While IL-17-targeted therapies (e.g., monoclonal antibodies) show promise in preclinical models, clinical outcomes remain heterogeneous, with controversies regarding cardiac adverse events (e.g.,coronary artery disease, pericarditis and atrial fibrillation) in autoimmune populations. Mechanistic insights emphasize IL-17's interactions with lipid metabolism, thrombotic pathways, and immune cross-talk. However, conflicting evidence on its protective versus detrimental effects necessitates further translational research. This review underscores the need for rigorous clinical trials to validate IL-17 modulation strategies in CVDs, balancing therapeutic benefits against potential adverse effects.

23 September 2021 in Human Gene Therapy
Verified
Journal Article
Closed access
Weidong QinWeidong Qin
Weidong Qin
LSLei Sun
Lei Sun
MDMei Dong
Mei Dong
GAGuipeng An
Guipeng An
KZKai Zhang
Kai Zhang
XMXiao Meng
Xiao Meng
Immune system dysfunction causes dysregulation of immune homeostasis, which in turn leads to autoimmune diseases. Regulatory T cells (Tregs) are a specialized T cell subpopulation that maintain peripheral tolerance and immune homeostasis. Diabetic patients are at an increased risk of developing cardiovascular diseases; thus, in terms of coronary risk, diabetes mellitus (DM) is considered coronary heart disease equivalent. Accumulating evidence indicates that Tregs play an important role in protecting against the development of various cardiovascular diseases. In this review, we provide an overview of the role of Tregs in the pathogenesis of DM, including type 1 DM, type 2 DM, latent autoimmune diabetes of adults, and gestational DM. In addition, we discuss the role of Tregs in diabetic complications, including cardiovascular diseases, nephropathy, neuropathy, and retinopathy. Tregs play a beneficial role in the pathogenesis of DM and diabetic complications, although the precise molecular mechanisms underlying the protective effect of Tregs against DM are still obscure. Collectively, modification of Tregs may provide a promising and novel future strategy for the prevention and therapy of DM and diabetic complications.

17 March 2021 in Human Gene Therapy
Verified
Journal Article
Closed access
Weidong QinWeidong Qin
Weidong Qin
WBWenwu Bai
Wenwu Bai
KLKeyin Liu
Keyin Liu
YLYa Liu
Ya Liu
XMXiao Meng
Xiao Meng
MZMingxiang Zhang
Mingxiang Zhang
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019 and rapidly spread to other provinces in China as well as other countries. In this study, 262 patients diagnosed with moderate to severe SARS-CoV-2 pneumonia in Wuhan, China, were analyzed. Data were compared between survivors and nonsurvivors. Of all the 262 patients, 23 (8.8%) patients died and 239 (91.2%) were discharged. The median age was 63.5 years and 46.9% of patients were male. The main complaints were fever (83.6%), cough (63.4%), and fatigue (49.2%) in the surviving group, while there were more complaints of dyspnea (39.1%) and shortness of breath (56.5%) in the nonsurviving group. The main comorbidities were hypertension (35.5%), diabetes mellitus (16.4%), and coronary artery disease (9.9%). Morbidity is higher in elderly patients with more comorbidities. Patients were mainly treated with nasal cannula (93.9%), while the nonsurviving group received more invasive mechanical ventilation (39.1%). Arbidol (80.9%), ribavirin (36.6%), oseltamivir (38.9%), interferon (16.4%), and ganciclovir (14.5%) were used for the antiviral treatment. In the nonsurviving group, the number of white blood cells (WBC) was significantly increased and lymphocytes were decreased, and lymphopenia was more common. The levels of aspartate transaminase (AST), brain natriuretic peptide (BNP), creatine kinase isoenzyme MB (CK-MB), lactate dehydrogenase (LDH), and C-reactive protein (CRP) were also significantly increased in the nonsurviving group. The adjusted hazard ratios (HRs) for association of known variables for all-cause mortality due to the coronavirus disease 2019 were 2.467 (95% confidence interval [CI], 1.007–6.044; p = 0.048) for shortness of breath and 1.025 (95% CI, 1.001–1.049; p = 0.042) for AST. Elderly patients with more comorbidities and complaints of dyspnea and shortness of breath had increased risk of death. Patients with lymphopenia and high levels of WBC, AST, BNP, CK-MB, LDH, and CRP may be more likely to deteriorate.

7 April 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MSMing Song
Ming Song
HDHonggang Dai
Honggang Dai
QZQuan Zhou
Quan Zhou
XMXiao Meng
Xiao Meng
Diabetic cardiomyopathy is a notable microvascular complication of diabetes, characterized primarily by myocardial fibrosis and functional abnormalities. Long-term hyperglycemia induces excessive activation and recruitment of immune cells and triggers the cascade of inflammatory responses, resulting in systemic and local cardiac inflammation. Emerging evidence highlights the significant roles of immunology in modulating the pathology of diabetic cardiomyopathy. As the primary effectors of inflammatory reactions, immune cells are consistently present in cardiac tissue and can be recruited under pathological hyperglycemia circumstances. A disproportionate favor to proinflammatory types of immune cells and the increased proinflammatory cytokine levels mediate fibroblast proliferation, phenotypic transformation, and collagen synthesis and ultimately rise to cardiac fibrosis and hypertrophy. Meanwhile, the severity of cardiac fibrosis is also strongly associated with the diverse phenotypes and phenotypic alterations of the immune cells, including macrophages, dendritic cells, mast cells, neutrophils, and natural killer cells in innate immunity and CD4+ T lymphocytes, CD8+ T lymphocytes, and B lymphocytes in adaptive immunity. In this review, we synthesized the current analysis of the critical role played by the immune system and its components in the progression of diabetic cardiomyopathy. Finally, we highlight preclinical and clinical immune targeting strategies and translational implications.

11 January 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
QKQingyu Kong
Qingyu Kong
XXXue Xu
Xue Xu
MLMeng Li
Meng Li
XMXiao Meng
Xiao Meng
ZCZhao Cuifen
Zhao Cuifen
XYXiaorong Yang
Xiaorong Yang
Background: Myocarditis is characterized by high disability and mortality, and imposes a severe burden on population health globally. However, the latest global magnitude and secular trend of myocarditis burden have not been reported. Objective: This study aimed to delineate the epidemiological characteristics of myocarditis burden globally for optimizing targeted prevention and research. Methods: Based on the Global Burden of Disease Study 2019, the myocarditis burden from 1990 to 2019 was modeled using the Cause of Death Ensemble tool, DisMod-MR, and spatiotemporal Gaussian regression. We depicted the epidemiology and trends of myocarditis by sex, age, year, region, and sociodemographic index (SDI). R program version 4.2.1 (R Project for Statistical Computing) was applied for all statistical analyses, and a 2-sided P-value of <.05 was considered statistically significant. Results: The number of incident cases (1,268,000) and deaths (32,450) associated with myocarditis in 2019 increased by over 1.6 times compared with the values in 1990 globally. On the other hand, the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) decreased slightly from 1990 to 2019. The disability-adjusted life years (DALYs) decreased slightly in the past 3 decades, while the age-standardized DALY rate (ASDR) decreased greatly from 18.29 per 100,000 person-years in 1990 to 12.81 per 100,000 person-years in 2019. High SDI regions always showed a more significant ASIR. The ASIR slightly decreased in all SDI regions between 1990 and 2019. Middle SDI regions had the highest ASMR and ASDR in 2019. Low SDI regions had the lowest ASMR and ASDR in 2019. The age-standardized rates (ASRs) of myocarditis were higher among males than among females from 1990 to 2019 globally. All ASRs among both sexes had a downward trend, except for the ASMR among males, which showed a stable trend, and females had a more significant decrease in the ASDR than males. Senior citizens had high incident cases and deaths among both sexes in 2019. The peak numbers of DALYs for both sexes were noted in the under 1 age group in 2019. At the national level, the estimated annual percentage changes in the ASRs had significant negative correlations with the baseline ASRs in 1990. Conclusions: Globally, the number of incident cases and deaths associated with myocarditis have increased significantly. On the other hand, the ASRs of myocarditis showed decreasing trends from 1990 to 2019. Males consistently showed higher ASRs of myocarditis than females from 1990 to 2019 globally. Senior citizens gradually predominated in terms of myocarditis burden. Policymakers should establish targeted control strategies based on gender, region, age, and SDI; strengthen aging-related health research; and take notice of the changes in the epidemic characteristics of myocarditis.

29 June 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
KZKai Zhang
Kai Zhang
YLYunyi Li
Yunyi Li
XGXiao Ge
Xiao Ge
LMLinlin Meng
Linlin Meng
JKJing Kong
Jing Kong
XMXiao Meng
Xiao Meng
Aims/Introduction: Regulatory T cells (Tregs) have protected against many cardiovascular diseases. This study was intended to explore the effect of Tregs on diabetic cardiomyopathy (DCM) using a db/db mouse model.Materials and methods: Eight‐week‐old male db/db mice were randomly divided into four groups: the control group, administered 200 μL phosphate‐buffered saline; the small‐dose Treg group, administered 105 Tregs; the large‐dose Treg group, administered 106 Tregs; and the PC group, administered 100 μg anti‐CD25 specific antibody (PC61) and 106 Tregs. After 12 weeks, mice were euthanized. Transthoracic echocardiography was carried out at the beginning and end of the experiment. Relevant basic experiments to evaluate the effects of Tregs on DCM were carried out.Results: Echocardiography showed that the impaired diastolic and systolic functions were significantly improved in mice administered large‐dose Tregs. Large‐dose Tregs significantly ameliorated myocardial hypertrophy and fibrosis, and decreased hypertrophic gene expression and collagen deposition. The protective effects of Tregs on diabetic hearts were associated with decreased oxidative stress, inflammatory response and apoptosis. In addition, Tregs promoted the activation of the phosphatidylinositol 3‐kinase–protein kinase B signaling pathway, whereas they inhibited extracellular signal‐regulated kinase 1/2 and Jun N‐terminal kinase phosphorylation, which might be responsible for the cardioprotective role of Tregs against DCM.Conclusions: Tregs ameliorated myocardial hypertrophy and fibrosis, improved cardiac dysfunction, and protected against DCM progression in db/db mice. The mechanisms involved a decrease of inflammatory response, oxidative stress and apoptosis, which might be mediated by phosphatidylinositol 3‐kinase–protein kinase B and mitogen‐activated protein kinase pathways. Hence, Tregs might serve as a promising therapeutic approach for DCM treatment.